ALT News and Press, Altimmune Inc. From 06/05/24

Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with MASH biopsy readouts in Q1 2025 Based on a quantitative systems pharmacology (QSP) comp...

2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...

2024-05-30 16:10:00 ET Summary The global market for GLP-1 therapies now looks on pace to top $100 billion. GLP-1 pioneers such as Eli Lilly, Novo Nordisk, could be joined by new players Amgen, Altimmune, Pfizer, Viking, Roche, and privately held Boehringer Ingelheim that have GLP...

2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...

Do you, or did you, own shares of Altimmune, Inc. (NASDAQ:ALT)? Did you purchase your shares between December 1, 2023 and April 26, 2024, inclusive? Did you lose money in your investment in Altimmune, Inc.? Do you want to discuss your rights? NEW YORK, NY / ACCESSWIRE / May 30...

2024-05-29 16:07:48 ET Summary Altimmune's pipeline prospect, pemvidutide, has the potential to be a best-in-class therapy for obesity and nonalcoholic steatohepatitis. Pemvidutide has shown promising results in clinical trials, including significant weight loss and improvements i...

2024-05-28 17:45:19 ET Summary Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease. The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results i...

2024-05-28 16:13:42 ET Summary Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen in obesity. A phase 2 trial in metabolic dysfunction-associated steatohepatitis, or MASH, is underway, and set to produce a ...

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Altimmune, Inc. (NASDAQ: ALT)? Did you purchase your shares between December 1, 2023 and April 26, 2024, inclusive? Did you lose money in your investment in Altimmune...

New York, New York--(Newsfile Corp. - May 27, 2024) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and reminds investors of the July 5, 2024 deadline to seek the role of l...